Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Documenting Physical Therapy Dose for Individuals With Cerebral Palsy: A Quality Improvement Initiative.

Bailes AF, Strenk ML, Quatman-Yates C, Hobart J, Furnier A.

Pediatr Phys Ther. 2019 Jul;31(3):234-241. doi: 10.1097/PEP.0000000000000614.

PMID:
31206504
2.

Low back pain.

Germon T, Clifford D, Lee W, Hobart J.

Lancet. 2018 Dec 15;392(10164):2547. doi: 10.1016/S0140-6736(18)32220-7. No abstract available.

PMID:
30563634
3.

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.

Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J; ENHANCE study investigators.

CNS Drugs. 2019 Jan;33(1):61-79. doi: 10.1007/s40263-018-0586-5.

4.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326. [Epub ahead of print]

PMID:
30381987
5.

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.

Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T.

Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248. doi: 10.1177/1756286418803248. eCollection 2018. Review.

6.

The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content.

Kirsch BM, Burke L, Hobart J, Angulo D, Walker PS.

J Drugs Dermatol. 2018 Jul 1;17(7):707-714.

PMID:
30005091
7.

Validating the portal population of the United Kingdom Multiple Sclerosis Register.

Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H, Griffiths D, Noble DG, Jones KH, Al-Din A, Craner M, Evangelou N, Harman P, Harrower T, Hobart J, Husseyin H, Kasti M, Kipps C, McDonnell G, Owen C, Pearson O, Rashid W, Wilson H, Ford DV.

Mult Scler Relat Disord. 2018 Aug;24:3-10. doi: 10.1016/j.msard.2018.05.015. Epub 2018 May 25.

PMID:
29860199
8.

Testing patient-reported outcome measurement equivalence in multinational clinical trials: An exemplar using the 12-item Multiple Sclerosis Walking Scale.

Dib H, Tamam Y, Terzi M, Hobart J.

Mult Scler J Exp Transl Clin. 2017 Sep 1;3(3):2055217317728740. doi: 10.1177/2055217317728740. eCollection 2017 Jul-Sep.

9.

Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force.

Powers JH 3rd, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, Isaac M, Vamvakas S, Slagle A, Molsen E, Burke LB.

Value Health. 2017 Jan;20(1):2-14. doi: 10.1016/j.jval.2016.11.005. Epub 2017 Jan 10.

10.

Brain health: time matters in multiple sclerosis.

Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T.

Mult Scler Relat Disord. 2016 Sep;9 Suppl 1:S5-S48. doi: 10.1016/j.msard.2016.07.003. Epub 2016 Jul 7. Review.

11.

Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S, Coyle PK.

Mult Scler. 2017 Apr;23(4):604-613. doi: 10.1177/1352458516657441. Epub 2016 Jul 11.

12.

An investigation of commonly prescribed stretches of the ankle plantarflexors in people with Multiple Sclerosis.

Ofori J, Freeman J, Logan A, Rapson R, Zajieck J, Hobart J, Marsden J.

Clin Biomech (Bristol, Avon). 2016 Aug;37:22-26. doi: 10.1016/j.clinbiomech.2016.05.013. Epub 2016 Jun 1.

PMID:
27286554
13.

Measuring spinal surgical success: the proportion achieving acceptable symptoms: Keep it simple but not simplistic.

Hobart J.

Spine J. 2016 Apr;16(4 Suppl):S19-20. doi: 10.1016/j.spinee.2016.01.221.

PMID:
26996054
14.

Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36.

Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D, Watson C.

Value Health. 2015 Nov;18(7):A713. doi: 10.1016/j.jval.2015.09.2688. Epub 2015 Oct 20. No abstract available.

15.

Measuring the Impact of Multiple Sclerosis: Enhancing the Performance of the Msis-29 and Msws-12.

Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D, Watson C.

Value Health. 2015 Nov;18(7):A709-10. doi: 10.1016/j.jval.2015.09.2670. Epub 2015 Oct 20. No abstract available.

16.

Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.

Walton MK, Powers JH 3rd, Hobart J, Patrick D, Marquis P, Vamvakas S, Isaac M, Molsen E, Cano S, Burke LB; International Society for Pharmacoeconomics and Outcomes Research Task Force for Clinical Outcomes Assessment.

Value Health. 2015 Sep;18(6):741-52. doi: 10.1016/j.jval.2015.08.006. Epub 2015 Aug 24.

17.

Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results.

Mehta L, McNeill M, Hobart J, Wyrwich KW, Poon JL, Auguste P, Zhong J, Elkins J.

Mult Scler J Exp Transl Clin. 2015 Aug 5;1:2055217315596993. doi: 10.1177/2055217315596993. eCollection 2015 Jan-Dec.

18.

Measuring arm function early after stroke: is the DASH good enough?

Baker K, Barrett L, Playford ED, Aspden T, Riazi A, Hobart J.

J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):604-10. doi: 10.1136/jnnp-2015-310557. Epub 2015 Jul 15.

PMID:
26180212
19.

People receiving unnecessary treatments: accurate diagnosis is key.

Germon T, Hobart J.

BMJ. 2015 Jun 2;350:h2962. doi: 10.1136/bmj.h2962. No abstract available.

PMID:
26036430
20.

Definitions, diagnosis, and decompression in spinal surgery: problems and solution.

Germon TJ, Hobart JC.

Spine J. 2015 Mar 2;15(3 Suppl):S5-8. doi: 10.1016/j.spinee.2014.12.147. No abstract available.

PMID:
25708140
21.

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.

Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J.

Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.

22.

Lending a hand: can DASH items help ABILHAND improve manual ability measurement in multiple sclerosis?

Barrett L, Cano S, Zajicek J, Hobart J.

Mult Scler. 2015 Apr;21(5):612-21. doi: 10.1177/1352458514549396. Epub 2015 Jan 12.

PMID:
25583836
23.

Is NICE guidance for identifying lumbar nerve root compression misguided?

Germon T, Singleton W, Hobart J.

Eur Spine J. 2014 Apr;23 Suppl 1:S20-4. doi: 10.1007/s00586-014-3233-y. Epub 2014 Feb 19.

24.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

25.

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.

Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Cano MG, McManus D, Mallik S, Hobart J; CUPID investigator group.

Lancet Neurol. 2013 Sep;12(9):857-865. doi: 10.1016/S1474-4422(13)70159-5. Epub 2013 Jul 13. Review.

26.

Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis.

Hobart J, Cano S, Baron R, Thompson A, Schwid S, Zajicek J, Andrich D.

Mult Scler. 2013 Nov;19(13):1773-83. doi: 10.1177/1352458513483378. Epub 2013 Apr 10.

PMID:
23574800
27.

Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.

Hobart J, Blight AR, Goodman A, Lynn F, Putzki N.

Neurology. 2013 Apr 16;80(16):1509-17. doi: 10.1212/WNL.0b013e31828cf7f3. Epub 2013 Mar 27. Review.

PMID:
23535489
28.

Evaluating change in mobility in people with multiple sclerosis: relative responsiveness of four clinical measures.

Freeman J, Walters R, Ingram W, Slade A, Hobart J, Zajicek J.

Mult Scler. 2013 Oct;19(12):1632-9. doi: 10.1177/1352458513482373. Epub 2013 Mar 25.

PMID:
23530002
29.

Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach.

Posner HB, Cano S, Carrillo MC, Selnes O, Stern Y, Thomas RG, Zajicek J, Hobart J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S56-60. doi: 10.1016/j.jalz.2012.10.008.

PMID:
23391006
30.

Interspinous spacers for lumbar foraminal stenosis: formal trials are justified.

Hobart J, Gilkes C, Adams W, Germon T.

Eur Spine J. 2013 Mar;22 Suppl 1:S47-53. doi: 10.1007/s00586-012-2650-z. Epub 2013 Jan 25.

31.

Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory.

Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S10-20. doi: 10.1016/j.jalz.2012.08.006. Epub 2012 Dec 17.

PMID:
23253779
32.

Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods.

Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S4-9. doi: 10.1016/j.jalz.2012.08.005. Epub 2012 Dec 17.

PMID:
23253777
33.

Can the ABILHAND handle manual ability in MS?

Barrett LE, Cano SJ, Zajicek JP, Hobart JC.

Mult Scler. 2013 May;19(6):806-15. doi: 10.1177/1352458512462919. Epub 2012 Oct 24.

PMID:
23095289
34.

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group.

J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125-32. doi: 10.1136/jnnp-2012-302468. Epub 2012 Jul 12.

PMID:
22791906
35.

What sample sizes for reliability and validity studies in neurology?

Hobart JC, Cano SJ, Warner TT, Thompson AJ.

J Neurol. 2012 Dec;259(12):2681-94. doi: 10.1007/s00415-012-6570-y. Epub 2012 Jun 24.

PMID:
22729386
36.

Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's disease.

Bladh S, Nilsson MH, Hariz GM, Westergren A, Hobart J, Hagell P.

J Neurol. 2012 Apr;259(4):729-38. doi: 10.1007/s00415-011-6254-z. Epub 2011 Sep 29.

PMID:
21956376
37.

A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS).

Riazi A, Porter B, Chataway J, Thompson AJ, Hobart JC.

Health Qual Life Outcomes. 2011 Sep 26;9:80. doi: 10.1186/1477-7525-9-80.

38.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

39.

The problem with health measurement.

Cano SJ, Hobart JC.

Patient Prefer Adherence. 2011;5:279-90. doi: 10.2147/PPA.S14399. Epub 2011 Jun 14.

40.

Clinical and methodological precision of spinal navigation assisted by 3D intraoperative O-arm radiographic imaging.

Oertel MF, Hobart J, Stein M, Schreiber V, Scharbrodt W.

J Neurosurg Spine. 2011 Apr;14(4):532-6. doi: 10.3171/2010.10.SPINE091032. Epub 2011 Jan 28.

PMID:
21275555
41.

Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis.

Cano SJ, Barrett LE, Zajicek JP, Hobart JC.

Mult Scler. 2011 Feb;17(2):214-22. doi: 10.1177/1352458510385269. Epub 2010 Oct 14.

PMID:
20947530
42.
43.

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.

Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, Hobart JC.

J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1363-8. doi: 10.1136/jnnp.2009.204008. Epub 2010 Sep 29.

PMID:
20881017
44.

Effect sizes can be misleading: is it time to change the way we measure change?

Hobart JC, Cano SJ, Thompson AJ.

J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):1044-8. doi: 10.1136/jnnp.2009.201392. Epub 2010 Jul 13.

PMID:
20627964
45.

Modafinil for multiple sclerosis fatigue: does it work?

Littleton ET, Hobart JC, Palace J.

Clin Neurol Neurosurg. 2010 Jan;112(1):29-31. doi: 10.1016/j.clineuro.2009.09.004. Epub 2009 Oct 17.

PMID:
19837509
46.

The size of the treatment effect: do patients and proxies agree?

van der Linden FA, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BM.

BMC Neurol. 2009 Mar 25;9:12. doi: 10.1186/1471-2377-9-12.

47.

Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies.

Cano SJ, Riazi A, Schapira AH, Cooper JM, Hobart JC.

Mov Disord. 2009 May 15;24(7):984-92. doi: 10.1002/mds.22420.

PMID:
19224613
48.

Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods.

Hobart J, Cano S.

Health Technol Assess. 2009 Feb;13(12):iii, ix-x, 1-177. doi: 10.3310/hta13120. Review.

49.

The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?

Cano SJ, Warner TT, Thompson AJ, Bhatia KP, Fitzpatrick R, Hobart JC.

Health Qual Life Outcomes. 2008 Aug 6;6:58. doi: 10.1186/1477-7525-6-58.

50.

Watch out, watch out, the FDA are about.

Cano SJ, Hobart JC.

Dev Med Child Neurol. 2008 Jun;50(6):408-9. doi: 10.1111/j.1469-8749.2008.00408.x. No abstract available.

Supplemental Content

Loading ...
Support Center